These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 14551179

  • 1. Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.
    Skrumsager BK, Nielsen KK, Müller M, Pabst G, Drake PG, Edsberg B.
    J Clin Pharmacol; 2003 Nov; 43(11):1244-56. PubMed ID: 14551179
    [Abstract] [Full Text] [Related]

  • 2. Intravenous pharmacokinetics, oral bioavailability and dose proportionality of ragaglitazar, a novel PPAR-dual activator in rats.
    Jagannath K, Chaluvadi MR, Mullangi R, Mamidi NV, Srinivas NR.
    Biopharm Drug Dispos; 2004 Oct; 25(7):323-8. PubMed ID: 15386480
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic and pharmacodynamic assessments of the dipeptidyl peptidase-4 inhibitor PHX1149: double-blind, placebo-controlled, single- and multiple-dose studies in healthy subjects.
    O'Farrell AM, van Vliet A, Abou Farha K, Cherrington JM, Campbell DA, Li X, Hanway D, Li J, Guler HP.
    Clin Ther; 2007 Aug; 29(8):1692-705. PubMed ID: 17919550
    [Abstract] [Full Text] [Related]

  • 4. Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.
    Ebdrup S, Pettersson I, Rasmussen HB, Deussen HJ, Frost Jensen A, Mortensen SB, Fleckner J, Pridal L, Nygaard L, Sauerberg P.
    J Med Chem; 2003 Apr 10; 46(8):1306-17. PubMed ID: 12672231
    [Abstract] [Full Text] [Related]

  • 5. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects: a 12-week, double-blind, placebo-controlled dose-ranging study with an open pioglitazone arm.
    Saad MF, Greco S, Osei K, Lewin AJ, Edwards C, Nunez M, Reinhardt RR, Ragaglitazar Dose-Ranging Study Group.
    Diabetes Care; 2004 Jun 10; 27(6):1324-9. PubMed ID: 15161783
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study.
    Sanwald-Ducray P, Liogier D'ardhuy X, Jamois C, Banken L.
    Clin Pharmacol Ther; 2010 Aug 10; 88(2):197-203. PubMed ID: 20336066
    [Abstract] [Full Text] [Related]

  • 10. The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin.
    Tonstad S, Retterstøl K, Ose L, Ohman KP, Lindberg MB, Svensson M.
    Metabolism; 2007 Sep 10; 56(9):1285-92. PubMed ID: 17697874
    [Abstract] [Full Text] [Related]

  • 11. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul 10; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 12. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-γ agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects.
    Kim JW, Kim JR, Yi S, Shin KH, Shin HS, Yoon SH, Cho JY, Kim DH, Shin SG, Jang IJ, Yu KS.
    Clin Ther; 2011 Nov 10; 33(11):1819-30. PubMed ID: 22047812
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans.
    Ericsson H, Hamrén B, Bergstrand S, Elebring M, Fryklund L, Heijer M, Ohman KP.
    Drug Metab Dispos; 2004 Sep 10; 32(9):923-9. PubMed ID: 15319332
    [Abstract] [Full Text] [Related]

  • 18. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 10; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 19. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.
    Chakrabarti R, Vikramadithyan RK, Misra P, Hiriyan J, Raichur S, Damarla RK, Gershome C, Suresh J, Rajagopalan R.
    Br J Pharmacol; 2003 Oct 10; 140(3):527-37. PubMed ID: 12970088
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK, Cheng G, Tang J, Song J, Peng WX.
    Clin Ther; 2009 May 10; 31(5):1022-36. PubMed ID: 19539103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.